Shares of Sage Therapeutics Inc. (NASDAQ:SAGE) have been assigned a consensus recommendation of “Buy” from the twelve research firms that are presently covering the company. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and ten have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $73.89.

A number of equities analysts recently issued reports on the company. BMO Capital Markets reiterated a “buy” rating on shares of Sage Therapeutics in a report on Tuesday, July 12th. Cowen and Company reiterated a “buy” rating on shares of Sage Therapeutics in a report on Wednesday, June 8th. Canaccord Genuity set a $110.00 target price on Sage Therapeutics and gave the stock a “buy” rating in a report on Tuesday, September 6th. Chardan Capital reiterated a “sell” rating on shares of Sage Therapeutics in a report on Wednesday, June 8th. Finally, Zacks Investment Research upgraded Sage Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 target price on the stock in a report on Thursday, July 7th.

In related news, insider Albert Robichaud sold 22,000 shares of Sage Therapeutics stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $40.00, for a total value of $880,000.00. Following the completion of the sale, the insider now owns 140,222 shares of the company’s stock, valued at approximately $5,608,880. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Kimi Iguchi sold 5,000 shares of Sage Therapeutics stock in a transaction dated Tuesday, July 12th. The stock was sold at an average price of $49.55, for a total value of $247,750.00. Following the completion of the sale, the chief financial officer now directly owns 83,739 shares of the company’s stock, valued at approximately $4,149,267.45. The disclosure for this sale can be found here. Insiders own 5.60% of the company’s stock.

A number of large investors have recently made changes to their positions in the company. Legal & General Group Plc raised its stake in shares of Sage Therapeutics by 17.2% in the first quarter. Legal & General Group Plc now owns 4,146 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 607 shares during the period. Teacher Retirement System of Texas raised its stake in shares of Sage Therapeutics by 38.2% in the second quarter. Teacher Retirement System of Texas now owns 3,522 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 973 shares during the period. Bessemer Group Inc. raised its stake in shares of Sage Therapeutics by 3.1% in the first quarter. Bessemer Group Inc. now owns 33,849 shares of the biopharmaceutical company’s stock valued at $1,085,000 after buying an additional 1,019 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Sage Therapeutics by 129.1% in the third quarter. BNP Paribas Arbitrage SA now owns 2,369 shares of the biopharmaceutical company’s stock valued at $109,000 after buying an additional 1,335 shares during the period. Finally, ProShare Advisors LLC raised its stake in shares of Sage Therapeutics by 5.9% in the second quarter. ProShare Advisors LLC now owns 27,110 shares of the biopharmaceutical company’s stock valued at $817,000 after buying an additional 1,500 shares during the period. 82.63% of the stock is owned by institutional investors.

Sage Therapeutics (NASDAQ:SAGE) traded down 3.70% during trading on Thursday, hitting $44.20. 209,875 shares of the company’s stock traded hands. Sage Therapeutics has a 52-week low of $26.28 and a 52-week high of $62.64. The company’s market cap is $1.42 billion. The company’s 50 day moving average price is $41.59 and its 200 day moving average price is $36.89.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by $0.06. Analysts expect that Sage Therapeutics will post ($4.38) earnings per share for the current year.

Sage Therapeutics Company Profile

SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor.

5 Day Chart for NASDAQ:SAGE

Receive News & Stock Ratings for Sage Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sage Therapeutics Inc. and related stocks with our FREE daily email newsletter.